RECOVER IMMUNE HEALTH

AUTOIMMUNE REHEALTH

antiageicon

BENEFITS OF STEM CELLS THERAPY

ANTI-INFLAMMATORY

Stem Cell Therapy aids in returning the bodies immune system to normal functional state and a drastic reduction in the patient’s inflammatory markers. This anti-inflammatory effect may last for years leading to ease in pain and faster recovery.

REGULATE THE IMMUNE SYSTEM

Stem Cells have the unique ability to regulate the immune system by increasing our regulatory T cells. This allows our system to halt pathological responses while preserving its ability to fight disease. After therapy, most patients will have a decrease in pro-inflammatory markers TNF‐α and IL-6, and most importantly the benefit of feeling well

THERAPEUTIC BENEFITS

In addition, to regulating the immune system, stem cell therapy may help with healing and recovery. Most importantly, it has been shown to have no serious adverse effects.

AUTOIMMUNE - REHEALTH

The immune system is naturally complex, with many components ultimately working together to maintain and regulate our blood system. All diseses have a direct correlation with immune dysfunction. One of the immune systems main function is to protect the body from attack of foreign pathogens and toxins[1]. The capacity to distinguish between “self” and “non-self” substances plays a central role in the process of immunity[2,3]: autoimmune disorders are the result of the breakdown of this self-tolerance[4].

The pharmacologic options for autoimmune disorders are mainly based on immunosuppressive activities that minimize or delay cellular damages in the affected organs rather than regulating or controlling the autoimmune process[2,5].

Studies have shown the potential of MSCs in treating autoimmune disorders. MSCs can be used as a treatment modality to regulate the immune system based on their properties . MSCs secrete molecules that can control the T cell response by increasing the amount of regultory T cells circulating in our body. These molecules secreted by MSCs also inhibit proliferation and function of cytotoxic T cells, natural killer cells, and B cells which could potentially prevent priming of naive T cells needed to initiate autoimmune diseases [6,10-12]. The dynamic secretion pattern and the immunomodulatory properties of MSCs make these cells phenomenal candidates for the treatment of many different autoimmune diseases.

GET A FREE DISCOVERY CALL

OR

CONTACT US

Let us help you Recover your health back! Transform your life now with our Regenerative Therapies!

 
REFERENCES

1. Haque N, Ramasamy TS, Kasim NHA. Mechanisms of mesenchymal stem cells for autoimmune disease treatment. In: Pham P. (eds). Stem cell transplantation for autoimmune diseases and inflammation. Stem Cells in Clinical Applications. Springer, Cham. 2019.
2. Rioux JD, Abbas AK. Paths to understanding the genetic basis of autoimmune disease. Nature. 2005. 435:584.
3. Yang SH, Gao CY, li L, Chang C, et al. The molecular basis of immune regulation in autoimmunity. Clin Sci. 2018. 132(1):43-67.
4. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015. 125(6):2228-33.
5. Chandrashekara S. The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review: Indian J Pharmacol. 2012. 44(6):665-71.}
6. Gao F, Chiu SM, Motan DAL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016. 7:e2062.
7. Kimbrel EA, Kouris NA, Yavanian GJ, et al. Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev. 2014. 23(14):1611-24.
8. Ganguly D, Haak S, Sisirak V, Reizis B. The role of dendritic cells in autoimmunity. Nat Rev Immunol. 2013. 13(8):566-77.
9. Sozzani S, Del Prete A, Bosisio D. Dendritic cell recruitment and activation in autoimmunity. J Autoimmun. 2017. 85:126-40.
10. Gebler A, Zabel O, Seliger. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Ther. 2012. 20(1):187-95.
11. Shlomchik MJ. Activating systemic autoimmunity: B’s, T’s and tolls. Curr Opin Immunol. 2009. 21(6):626-33.
12. Summers SA, Hoi A, Steinmetz OM, et al. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in primate nephropaty. J Autoimmun. 2010. 35(4):291-8.
13. Flodstrom-Tullberg M, Bryceson YT, Shi FD, Hoglund P, Ljunggren HG. Natural killer cells in human autoimmunity. Curr Opin Immunol. 2009. 21(6). 634-40.
14. Fogel LA, Yokoyama WM, French AR. Natural killer cells in human autoimmune disorders. Arthritis Res Ther. 2013. 15(4):216.